Clinical Cancer Research CR Balducci Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orimo, A.
Right arrow Articles by Muramatsu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orimo, A.
Right arrow Articles by Muramatsu, M.
Clinical Cancer Research Vol. 7, 3097-3105, October 2001
© 2001 American Association for Cancer Research

Regular Articles

Cancer-associated Myofibroblasts Possess Various Factors to Promote Endometrial Tumor Progression1

Akira Orimo2, Yasuhiro Tomioka, Yoshihiko Shimizu, Miyuki Sato, Satoko Oigawa, Koichi Kamata, Yasuhisa Nogi, Satoshi Inoue, Masakazu Takahashi, Toshio Hata and Masami Muramatsu

Departments of Biochemistry [A. O., M. S., Y. N., S. I., M. M.], Obstetrics and Gynecology [Y. T., S. O., T. H.], Pathology [Y. S., K. K.], and Future Program Research Division [M. M.], Saitama Medical School, 38 Moro-Hongo, Moroyama-machi, Iruma-gun Saitama 350-0495; Department of Pathology, Sasaki Institute, 2-2 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062 [M. T.]; and CREST, Japan Science and Technology Corporation, [A. O.] Tokyo 170-0013, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Myofibroblastic invasion associated with malignant epithelial cells of endometrial cancer as well as other cancers is often found in the interstitium. To assess the myofibroblastic-epithelial interaction, frozen sections from a total of 10 endometrial cancers with or without invasive myofibroblasts were immunohistochemically examined. Interestingly, the invasive myofibroblasts adjacent to malignant epithelial cells showed frequently intensive positive staining of several growth factors such as vascular endothelial growth factor (VEGF), insulin-like growth factor I, and epidermal growth factor, the cognate receptors such as Fetal liver kinase-1/Kinase Insert Domain-containing receptor/VEGF receptor-2, fms-like tyrosine kinase-1/VEGF receptor-1, and epidermal growth factor receptor, several cell cycle regulators such as cyclins and cyclin dependent kinases, and estrogen receptor {alpha}. Moreover, we indicated that the majority of the myofibroblasts as well as cancer epithelial cells are proliferating because of their positive staining of proliferating cell nuclear antigen and Ki-67. Furthermore, the myofibroblasts were also positive of hypoxia-inducible factor 1 {alpha}, which is a marker protein of hypoxia, probably followed by activation of VEGF-Flk-1 and VEGF-fms-like tyrosine kinase-1 signals, which could initiate angiogenesis. These findings suggest directly that the myofibroblasts might participate in the progression of tumor cells in terms of cancer cell growth stimulation and also activated initiation of angiogenesis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Tumorigenesis is a multistep process accompanied by genetic alterations of precancerous cells and simultaneously by building up the microenvironment that promotes transformation (1, 2, 3) . Consequently, epigenetic contributions from stroma cells surrounding cancer cells play important roles for formation of progressive neoplasm (4, 5, 6) . The features of stromal invasion in carcinomas are frequently shown in many cancers including breast, endometrium, prostate, lung, colon, and stomach. It is also known that the stroma is histopathologically composed of several supportive coconspirators such as fibroblasts, inflammatory cells, immune cells, smooth muscle cells, and endothelial cells (3 , 4) . Interestingly, fibroblasts constitute a major stromal compartment, and many of them associated with tumor cells are seen significantly differentiated into so-called "myofibroblasts" (7, 8, 9) , which are also found in the process of wound healing, possessing more reactive and plastic properties than normal fibroblasts. The trait of myofibroblasts containing both fibroblasts and smooth muscle cell lineages is defined by positive expression of stromal cell type markers such as prolyl 4-hydroxylase (10 , 11) , integrin {alpha}2ß1, vimentin, and CD34, and by positive expression of smooth muscle cell markers such as {alpha}-smooth muscle actin, smooth muscle myosin, calponin, and {alpha}1-integrin (9) . However, the differences between myofibroblasts and fibroblasts involved in the oncogenic ability are quite unknown. It was postulated previously that several tumorigenic features could be enhanced by coexistence of the fibroblasts and malignant epithelial cells. In brief, several in vitro coculture (12, 13, 14, 15) and in vivo xenografts studies (16, 17, 18, 19) , using both cells with a combination of various cell types among normal, initiated, and/or tumorigenic stages, have suggested that the fibroblasts could accelerate progression of malignant epithelial cells because of activated proteolysis (20 , 21) , increased cancer cell proliferation (14 , 15) , and attenuation of cancer cell death (18) . These consequences might be feasible in assessing the cancer cell progression mechanisms, although the molecular signaling of the fibroblasts-epithelial interaction is also still quite obscure.

We have tried to perform immunostaining of frozen sections from 10 independent endometrial cancer samples using different antibodies, which specifically recognize several key proteins involved in cell growth, cell cycle regulation, sex hormone activation, hypoxia, and angiogenesis. Significant positive staining of various factors in interstitial myofibroblasts has raised an interesting possibility that the myofibroblasts might actually support tumor progression.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Selection of Patients.
Between November 1998 and December 1999, 10 patients of all of the endometrial cancer patients (mean age, 60.3 years; range, 38–79 years) to whom uterectomy was performed were enrolled in the study under informed consent, according to no complication of chronic diseases. Additionally, any hormonal drugs such as GnRH agonist and progestogen had never been prescribed before the operation.

Antibody and Immunohistochemistry.
A small portion of each endometrial cancer mass was cut down and promptly embedded into Tissue-Tek O.C.T. Compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan). Then serial 4-µm frozen sections were generated and stained with H&E. Immunohistochemistry was performed sequentially as described previously (22) . Coverslides were fixed, preblocked in 10% normal goat or rabbit serum, and reacted using each first antibody. The reaction by first antibody was performed in 1:100–300 for mAb and in 1:400–600 for polyclonal antibody, respectively. Anti-prolyl 4-hydroxylase mAb (5B5; DAKO Corp., Carpinteria, CA), anti-integrin {alpha}2ß1 mAb (P1E6; DAKO Corp.), antivimentin mAb (V9; Santa Cruz Biotechnology, Inc.), and anti-CD34 mAb (QBEND10; Immunotech, Marsielle, France) were used as a positive marker of stromal cell lineage. In addition, anti-{alpha}-smooth muscle actin mAb (1A4; Sigma Chemical Co.) was used as a positive marker of smooth muscle cells, and anticytokeratin 8, 18, and 19 mAb (NCL-5D3; PROGEN, Heidelberg, Germany) was used as a positive marker of epithelial cells. Additionally, anti-VEGF3 polyclonal antibody (C-1; Santa Cruz Biotechnology, Inc.), anti-IGF-I polyclonal antibody (G-17; Santa Cruz Biotechnology, Inc.), anti-EGF mAb (Chemicon International Inc., Temecula, CA), anti-EGFR polyclonal antibody (1005)-G (Santa Cruz Biotechnology, Inc.), anti-Fetal liver kinase-1/Kinase Insert Domain-containing receptor/VEGFR-2 mAb (A-3; Santa Cruz Biotechnology, Inc.), and anti-fms-like tyosine kinase-1/VEGF receptor-1 polyclonal antibody (C-17; Santa Cruz Biotechnology, Inc.) were used as a marker of growth factors and the cognate receptors. As a marker of cell cycle regulators, anticyclin D1 mAb (R-124; Santa Cruz Biotechnology, Inc.), anticyclin D3 mAb (Upstate Biotechnology Inc., Waltham, MA), anticyclin A polyclonal antibody (A-3; Santa Cruz Biotechnology, Inc.), anti-cdk4 polyclonal antibody (C-22)-G (Santa Cruz Biotechnology, Inc.), and anti-cdk6 polyclonal antibody (C-21; Santa Cruz Biotechnology, Inc.) were also used. Moreover, anti-PCNA mAb (PC10; Santa Cruz Biotechnology, Inc.) and anti-Ki-67 polyclonal antibody (C-20; Santa Cruz Biotechnology, Inc.) were used as a marker of proliferating cells. In addition, anti-ER {alpha} polyclonal antibody (PA1–308; Affinity Bioreagents, Inc., Golden, CO), anti-PR mAb (MA1–410; Affinity Bioreagents, Inc.), and anti-EFP polyclonal antibody (23) were used as detection of sex hormone receptors and downstream target genes. Lastly, anti-HIF-1{alpha} mAb (clone H1{alpha}67; Novus Biologicals, Inc., Littleton, CO) was used as a marker of hypoxia. After biotinylated antirabbit IgG antibody, antimouse IgG antibody, or antigoat IgG antibody was reacted selectively, horseradish peroxidase-streptavidin and substrate solution were added. Then these sections were slightly stained by hematoxylin.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Immunohistochemical Identification of Myofibroblasts in Endometrial Cancer.
Serial frozen sections from 10 endometrial cancer samples were stained by H&E to classify them histologically into three pathological grades (G1–G3). We found that there were 3 cases with G1 grade, 4 cases with G2 grade, and 3 cases with G3 grade, respectively. Actually, 8 samples (from 3 to 10 in Table 1Citation ) showed significant stroma cell invasion in the interstitium, whereas 2 samples (1 and 2) showed little stroma cell invasion (data not shown). Herein, a view of the sample 6 (Y.U.) was representatively shown. Morphologically there were a number of fibroblasts with spindle-like appearance in the stroma invasion on the specimen stained by H&E (Fig. 1Citation , panel 1). To confirm them immunohistochemically, immunostaining was done using positive markers of stroma cell lineage including fibroblasts such as prolyl 4-hydroxylase (Fig. 1Citation , panel 2), integrin {alpha}2ß1 (Fig. 1Citation , panel 3), vimentin (Fig.1Citation , panel 4), and CD34 (data not shown), and using a strict positive marker of smooth muscle cell lineage such as {alpha}-smooth muscle actin (Fig. 1Citation , panel 5), which never reacts with fibroblasts. In the markers of stroma cell lineage, the anti-prolyl 4-hydroxylase antibody was reported as more specific to the fibroblasts than others showing no cross-reactivity, at least with other mesenchymal cell lineages such as lymphocytes, monocytes, dendritic cells, granulocytes (10 , 11) , and smooth muscle cells (data not shown). It was found that a number of cells in the interstitium were positive with respect to each marker on serial sections from the sample 6 (Fig. 1Citation , panels 2–5), suggesting that the majority of invasive stroma appears to be composed of a great many myofibroblasts, because positive signals of both markers of fibroblastic and smooth muscle cell lineage were colocalized. In contrast, anticytokeratin 8, 18, and 19 antibody, strictly specific to the epithelial cells, stained only the epithelial cells strongly but no stroma in the interstitium as was expected (Fig. 1Citation , panel 6).


View this table:
[in this window]
[in a new window]

  		Table 1 Summarized results of semiquantitive immunohistochemical staining of tumor-associated stroma in 10 endometrial cancersa

 


View larger version (92K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Immunohistochemical identification of myofibroblasts in endometrial cancer. A representative view of a sample (6 shown in Table 1Citation ) of 10 endometrial cancer samples is shown. A frozen section was stained by H&E (panel 1) and then serial sections were immunostained using following antibodies: panel 2, anti-prolyl 4-hydroxylase mAb; panel 3, anti-integrin {alpha}2ß1 mAb; panel 4, antivimentin mAb; panel 5, anti-{alpha}-smooth muscle actin mAb; panel 6, anticytokeratin 8, 18, and 19 mAb. Respective positive signals are shown as brown, and incidentally nuclear staining of whole cells is shown as blue or violet by hematoxylin. The colocalized intense staining of positive markers of stromal cells including fibroblasts and smooth muscle cells shows that almost all interstitial cells are occupied with myofibroblasts. EP, epithelial cells; CAF, carcinoma-associated myofibroblast; prolyl 4-h, prolyl 4-hydroxylase; {alpha}SMactin, {alpha}-smooth muscle actin. Scale bar, 100 µm.

 
Immunohistochemical Staining of Several Growth Factors and Cell Cycle Regulators in Invasive Carcinoma-associated Myofibroblasts.
First, we hypothesized that growth factors would be more feasible as the factor that mediates the myofibroblastic-epithelial interaction. A number of sections from 10 endometrial cancer samples were used for immunostaining. In Fig. 2ACitation , the representative views of invasive myofibroblasts in interstitial stroma (Fig. 2ACitation , panels 2, 4, 6, and 8), the vicinal tumor epithelial cells (Fig. 2ACitation , panels 2, 4, 6, and 8), and the portion of benign epithelial cells (Fig. 2ACitation , panels 9 and 10) were presented from the serial sections of the sample 6 that had also been shown in Fig. 1Citation , whereas malignant epithelial cells with few invasive myofibroblasts from sample 1 were also shown in Fig. 2ACitation , panels 1, 3, 5, and 7.




View larger version (210K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Immunohistochemical staining of several growth factors and cell cycle regulators in invasive carcinoma-associated myofibroblasts. A, representative views of 2 samples (1 and 6, shown in Table 1Citation ) of 10 endometrial cancer samples are shown. Panels 1, 3, 5, and 7 are from sample 1, and panels 2, 4, 6, 8, 9, and 10 are from sample 6. The benign regions (panels 9 and 10) from sample 6 are also shown. Each serial frozen section was immunostained using the following antibodies: panels 1, 2, and 9, anti-VEGF polyclonal antibody; panels 3, 4, and 10, anti-IGF-I polyclonal antibody; panels 5 and 6, anti-EGF mAb; and panels 7 and 8, anti-EGFR polyclonal antibody. EP, epithelial cells; CAF, carcinoma-associated fibroblast; BE, benign region. Scale bar, 100 µm. B, representative views of two samples (1 and 6) are shown as in (A). Similarly, here are views from sample 1 (panels 1, 3, 5, 7, and 9) and those from sample 6 (panels 2, 4, 6, 8, and 10). Panels 1 and 2, immunostaining with anticyclin D1 mAb; panels 3 and 4, anticyclin D3 mAb; panels 5 and 6, anticyclin A polyclonal antibody; panels 7 and 8, anti-cdk4 polyclonal antibody; and panels 9 and 10, anti-cdk6 polyclonal antibody. Positive signals are shown in brown, and incidental nuclear staining of whole cells is shown as blue or violet by hematoxylin. Abbreviations and scale bars are the same as in A.

 
Indeed, the myofibroblasts (Fig. 2ACitation , panels 2, 4, and 6) showed immunohistochemically significant positive staining of VEGF, IGF-I, and EGF, whereas vicinal malignant epithelial cells (Fig. 2ACitation , panels 2, 4, and 6) were quite less stained. In contrast, the malignant epithelial cells without invasive myofibroblasts (Fig. 2ACitation , panels 1, 3, and 5) showed strong staining of VEGF, IGF-I, and EGF, and the stain of VEGF (Fig. 2ACitation , panel 9) and IGF-I (Fig. 2ACitation , panel 10) in the benign epithelium was also shown strongly, indicating the down-regulation of these factors in malignant epithelial cells adjacent to invasive myofibroblasts, although there were differences among respective samples (data not shown). In addition, EGFR staining was strongly positive in invasive myofibroblasts (Fig. 2ACitation , panel 8), vicinal tumor epithelial cells (Fig. 2ACitation , panel 8), and tumor epithelial cells with few invasive myofibroblasts (Fig. 2ACitation , panel 7).

Next, we attempted immunostaining using various antibodies specific to cell cycle regulators such as cyclin D1, D3, cyclin A, cdk4, and cdk6. These regulators were significantly positive in invasive myofibroblasts even more than vicinal tumor epithelial cells (Fig. 2BCitation , panels 2, 4, 6, 8, and 10), whereas tumor epithelial cells with few invasive myofibroblasts also showed strong positive signals (Fig. 2BCitation , panels 1, 3, 5, and 7) of all of these factors. However, cdk6 signals appeared predominant in stroma (Fig. 2BCitation , panel 9), indicating that other interstitial cells also produce cdk6 in this sample. Then we performed immunostaining using each antibody that recognizes PCNA and Ki-67 to assess whether these cells are proliferating. There were positive PCNA and Ki-67 signals in both tumor epithelial cells and invasive myofibroblasts (Fig. 3Citation , panels 2 and 4) and also in tumor epithelial cells with few invasive myofibroblasts (Fig. 3Citation , panels 1 and 3). These results show that both the myofibroblasts and tumor epithelial cells are actually proliferating.



View larger version (95K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Immunohistochemical representation of proliferating cells in carcinoma-associated myofibroblasts. Photo from two samples (1 and 6) is shown. There are views (panels 1 and 3) from sample 1 and those (panels 2 and 4) from sample 6. Panels 1 and 2, immunostaining using anti-PCNA mAb; panels 3 and 4, using anti-Ki-67 polyclonal antibody. Positive signals are indicated as brown, and incidentally nuclear staining of whole cells is shown as blue or violet by hematoxylin. EP, epithelial cells; CAF, carcinoma-associated fibroblast. Scale bar, 100 µm.

 
Immunohistochemical Analysis of Sex Hormone Receptors and a Few Factors Implicated in Hypoxia and Angiogenesis in Cancer-associated Myofibroblasts.
Next, immunostaining of ER {alpha} was examined because of the feature of estrogen-dependent growth of endometrial cancer cells. The expression of EFP (22 , 23) and PR (24) , which are downstream target genes of ER {alpha} in the uterus, was also examined.

Invasive myofibroblasts showed significantly overlapped staining of ER {alpha} (Fig. 4Citation , panel 2), EFP (Fig. 4Citation , panel 4), and PR (Fig. 4Citation , panel 6), whereas respective signals of vicinal tumor epithelial cells were moderately positive in ER {alpha} (Fig. 4Citation , panel 2) and PR (Fig. 4Citation , panel 6) and almost negative in EFP (Fig. 4Citation , panel 4), suggesting the possible regulation by sex hormones even in the invasive myofibroblasts. In contrast, tumor epithelial cells with few invasive myofibroblasts also showed strong staining in ER {alpha} (Fig. 4Citation , panel 1), EFP (Fig. 4Citation , panel 3), and PR (Fig. 4Citation , panel 5). Lastly, we have attempted immunostaining of HIF1 {alpha}, which is a marker protein of hypoxia and also that of Flk-1 and Flt-1, which are markers for initiation of angiogenesis as the receptors of VEGF. In Fig. 5Citation , the immunoreactivity of HIF1 {alpha} (Fig. 5Citation , panel 1), Flk-1 (Fig. 5Citation , panel 2), and Flt-1 (Fig. 5Citation , panel 3) was significantly positive in invasive myofibroblasts, whereas vicinal tumor epithelial cells were also moderately positive in HIF1 {alpha} and Flk-1 but negligible in Flt-1. The significance of positive staining in invasive myofibroblasts is discussed later.



View larger version (77K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Immunohistochemical analysis of sex hormone receptors in carcinoma-associated myofibroblasts. The photo from two samples (1 and 6) is shown. There are views (panels 1, 3, and 5) from sample 1 and those (panels 2, 4, and 6) from sample 6. Panels 1 and 2, immunostaining using anti-ER {alpha} polyclonal antibody; panels 3 and 4, anti-EFP polyclonal antibody; and panels 5 and 6, anti-PR mAb. Positive signals are indicated as brown, and incidentally nuclear staining of whole cells is shown as blue or violet by hematoxylin. EP, epithelial cells; CAF, carcinoma-associated fibroblast. Scale bar, 100 µm.

 


View larger version (46K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Immunohistochemical analysis of a few factors implicated in hypoxia and angiogenesis in carcinoma-associated myofibroblasts. The photo from sample 6 is shown. Panel 1, immunostaining using anti-HIF-1{alpha} mAb; panel 2, anti-Flk-1/KDR/VEGFR-2 mAb; and panel 3, anti-Flt-1/VEGF receptor-1 polyclonal antibody. Positive signals are indicated as brown, and incidentally nuclear staining of whole cells are shown as blue or violet by hematoxylin. EP, epithelial cells; CAF, carcinoma-associated fibroblast. Scale bar, 100 µm.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The supportive role of stroma surrounding cancer cells, which is composed of majority of myofibroblasts, to tumor is originally demonstrated (4 , 5) . Interestingly, new reports are showing currently that myofibroblasts have oncogenic ability to promote not only tumor initiation but also the progression in the prostate cancer (19 , 25) . However, the molecular mechanism of a sort of tumorigenic ability in the myofibroblasts is still unknown.

Actually, it was reported previously that 83% of the whole curetteting samples from 204 endometrial cancers with G1–G3 grades showed significant stromal invasion adjacent to cancer epithelial cells (26) . Therefore, we have evaluated the immunoreactivity of several factors regarding cancer promotion in stroma surrounding the endometrial cancer cells.

This time, we have demonstrated that almost all of the cells of the invasive stroma in 4 (samples 3, 6, 7, and 8, shown in Table 1Citation ) of 8 endometrial cancer samples (from 3 to 10) are likely to be real myofibroblasts according to highly positive signals of prolyl 4-hydroxylase and {alpha}-smooth muscle actin, whereas the interstitium of the remaining 4 samples (4, 5, 9, and 10) probably consists of smooth muscle cells and other mesenchymal cells containing fewer myofibroblasts, because the cell population is less positive of prolyl 4-hydroxylase compared with more cell population positive of {alpha}-smooth muscle actin, integrin {alpha}2ß1 and vimentin (Table 1)Citation . Consistently, it was reported previously that myofibroblasts were composed of >80% of breast cancer stroma cells (27) . In future, double immunostaining using anti-prolyl 4-hydroxylase antibody and anti-{alpha}-smooth muscle actin antibody may be required to actually evaluate the correct ratio of myofibroblasts in the whole stroma.

The role of invasive myofibroblasts during tumorigenesis has been examined by several immunohistochemical studies and coculture systems with malignant cells showing elevated production of extracellular matrix proteins such as tenascin (28) and fibronectin (29) and altered secretion of metalloproteinases such as stromelysin-3 (20 , 21) and MMP-2 (30) , which are proteolytic enzymes. These findings suggested that the myofibroblasts might support cancer-invasive properties through facilitation of the initial attachment and also through infiltrative movement of cancer epithelial cells. In addition, regarding cell proliferation, previous reports have shown altered expression of many growth factors such as hepatic growth factor (15) , IGF-I and II (12 , 21) , TGF-ß1 (31) , connective tissue growth factor (31) , and platelet-derived growth factors receptor (32) in myofibroblasts cocultured with malignant cells, supporting the idea that these growth factors might help accelerate cell growth of malignant epithelial cells.

In this study, we have succeeded to immunohistochemically detect predominant positive signals in invasive myofibroblasts associated with malignant epithelial cells in actual endometrial cancer samples using respective antibodies of several factors involved in cell growth, cell cycle regulation, sex hormone activation, hypoxia, and angiogenesis. Interestingly, the invasive myofibroblasts showed significant positive signals of growth factors, such as VEGF, IGF-I, and EGF, and those of the cognate receptors, such as Flk-1 and Flt-1, which are receptors of VEGF, and EGFR, which was positively detected also in the vicinal epithelial cells. Therefore, it is likely that the invasive myofibroblasts take a share in stimulation of malignant epithelial cells through growth factor receptor signals in a paracrine manner and also stimulate themselves in an autocrine manner. Moreover, the invasive myofibroblasts were actually proliferating as exemplified by the significant positivity of cyclin D1, D3, cyclin A, cdk4, and cdk6, and also of PCNA and Ki-67.

From these observations, we strongly suggest the possibility that these growth factors would be important molecules, which mediate the myofibroblastic-epithelial interaction in carcinogenesis. Summarized results in Table 1Citation with predefined arbitrary scale show that the high expression of these factors in the invasive myofibroblasts is a common feature among most endometrial cancer samples (8 of 10). Notably, the more these factors are expressed, the more the cells appeared to infiltrate as myofibroblasts (see samples 3, 6, 7, and 8).

The present study is the first to actually demonstrate predominant existence of various growth factors, cell cycle regulators, and cell proliferating markers in the invasive myofibroblasts of endometrial cancer. Incidentally, it was reported previously that most myofibroblasts in nodular palmar fibromatosis were positive for Ki-67 and PCNA (33) . Also reported are several data indicating expression and existence of a few growth factors such as IGF-II (21) , TGF-ß1 (31) , and Connective Tissue Growth Factor (31) in invasive myofibroblasts of breast cancer, although their positive signals are not so dramatic.

On the other hand, nearly one-half of endometrial carcinoma has the feature of estrogen-dependent growth and, hence, estrogen is well known as one of the risk factors that stimulates the endometrial cancer progression (34 , 35) . As shown in Fig. 4Citation , the positive staining of ER {alpha} colocalized with EFP (22 , 23) and PR (24) , which are known as downstream genes of ER {alpha}, in the myofibroblasts is remarkable and suggests that ER {alpha} might be ligand-independently activated even in some specimens from postmenopausal women.

Next, the existence of a few angiogenic factors in myofibroblasts was examined, referring to previous reports, which had indicated the possible role of myofibroblasts implicated in angiogenesis (36 , 37) . It is currently believed that enhanced HIF1 {alpha} expression correlates with tumor growth and angiogenesis (38 , 39) , of which the mechanism is likely to be through up-regulation of VEGF expression (40) . Then the significant staining of HIF1 {alpha} and VEGF in the invasive myofibroblasts in this study lets us imagine the possibility of increased initiation of angiogenesis through activation of VEGF-Flk-1 and VEGF-Flt-1 signals in the interstitium.

Finally, it is recapitulated that our immunohistochemical data supported the cooperative role of the myofibroblasts involved in endometrial cancer cell progression because of accelerated cell proliferation and initiation of angiogenesis in vivo. Significantly, a previous clinical report about endometrial cancer has indicated the importance of stromal invasion in predicting prognosis, because many atypical hyperplasias with significant stromal invasion were more frequently accompanied by more invasive residual carcinomas compared with the one with less stromal invasion (26) . Hence, the evaluation of the pathological grades of endometrial cancers might be done seriously based on the insight into the existence of stromal invasion as well as malignant epithelial cells. In future, correlation among the extent of stromal invasion, existence of several growth factors, and the prognosis should be more positively evaluated, and it would also be worthy of examining carefully whether drug intervention into the paracrine factors and other signals of the stromal-epithelial interaction is applicable to therapeutic approach of cancer progression.


   ACKNOWLEDGMENTS
 
We thank members of the Masami Muramatsu laboratory and the Tosiho Hata laboratory for valuable advice.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants from the Ministry of Education, Science and Culture Japan, Sandoz Foundation, and Maruki Memorial Prize by Saitama Medical School (to A. O.). Back

2 To whom requests for reprints should be addressed, at Department of Biochemistry, Saitama Medical School, 38 Moro-Hongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan. Phone: 81-492-76-1490; Fax: 81-492-94-9751. E-mail: aorimo{at}saitama-med.ac.jp (to A. O.) or muramasa{at}saitama-med.ac.jp (to M. M.R). Back

3 The abbreviations used are: VEGF, vascular endothelial growth factor; IGF-I, insulin-like growth factor I; mAb, monoclonal antibody; EGF, epidermal growth factor; TGF, transforming growth factor; EGFR, epidermal growth factor receptor; cdk, cyclin-dependent kinase; ER {alpha}, estrogen receptor {alpha}; PR, progesterone receptor; EFP, estrogen responsive finger protein; PCNA, proliferating cell nuclear antigen; Flt-1, fms-like tyrosine kinase-1; HIF1 {alpha}, hypoxia-inducible factor 1 {alpha}. Back

Received 3/12/01; revised 7/23/01; accepted 7/23/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Murray M. J., Cunningham J. M., Parada L. F., Dautry F., Lebowitz P., Weinberg R. A. The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors. Cell, 33: 749-757, 1983.[CrossRef][Medline]
  2. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.[CrossRef][Medline]
  3. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.[CrossRef][Medline]
  4. Ronnov-Jessen L., Petersen O. W., Bissell M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev., 76: 69-125, 1996.[Abstract/Free Full Text]
  5. Kinzler K. W., Vogelstein B. Landscaping the cancer terrain. Science (Wash. DC), 280: 1036-1037, 1998.[Free Full Text]
  6. Skobe M., Fusenig N. E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA, 95: 1050-1055, 1998.[Abstract/Free Full Text]
  7. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-ß 1 induces {alpha}-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol., 122: 103-111, 1993.[Abstract/Free Full Text]
  8. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J. Cell Biol., 124: 401-404, 1994.[Free Full Text]
  9. Ronnov-Jessen L., Petersen O. W., Koteliansky V. E., Bissell M. J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Investig., 95: 859-873, 1995.
  10. Konttinen Y. T., Nykanen P., Nordstrom D., Saari H., Sandelin J., Santavirta S., Kouri T. DNA synthesis in prolyl 4-hydroxylase positive fibroblasts in situ in synovial tissue. An autoradiography-immunoperoxidase double labeling study. J. Rheumatol., 16: 339-345, 1989.[Medline]
  11. Janin A., Konttinen Y. T., Gronblad M., Karhunen P., Gosset D., Malmstrom M. Fibroblast markers in labial salivary gland biopsies in progressive systemic sclerosis. Clin. Exp. Rheumatol., 8: 237-242, 1990.[Medline]
  12. Cullen K. J., Smith H. S., Hill S., Rosen N., Lippman M. E. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res., 51: 4978-4985, 1991.[Abstract/Free Full Text]
  13. Singer C., Rasmussen A., Smith H. S., Lippman M. E., Lynch H. T., Cullen K. J. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res., 55: 2448-2454, 1995.[Abstract/Free Full Text]
  14. Atula S., Grenman R., Syrjanen S. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp. Cell. Res., 235: 180-187, 1997.[CrossRef][Medline]
  15. Nakamura T., Matsumoto K., Kiritoshi A., Tano Y., Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res., 57: 3305-3313, 1997.[Abstract/Free Full Text]
  16. Chung L. W., Chang S. M., Bell C., Zhau H. E., Ro J. Y., von Eschenbach A. C. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int. J. Cancer, 43: 1179-1187, 1989.[Medline]
  17. Camps J. L., Chang S. M., Hsu T. C., Freeman M. R., Hong S. J., Zhau H. E., von Eschenbach A. C., Chung L. W. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA, 87: 75-79, 1990.[Abstract/Free Full Text]
  18. Olumi A. F., Dazin P., Tlsty T. D. A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. Cancer Res., 58: 4525-4530, 1998.[Abstract/Free Full Text]
  19. Olumi A. F., Grossfeld G. D., Hayward S. W., Carroll P. R., Tlsty T. D., Cunha G. R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res., 59: 5002-5011, 1999.[Abstract/Free Full Text]
  20. Basset P., Bellocq J. P., Wolf C., Stoll I., Hutin P., Limacher J. M., Podhajcer O. L., Chenard M. P., Rio M. C., Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.[CrossRef][Medline]
  21. Singer C. F., Rasmussen A., Lippman M. E., Cullen K. J. Coexpression of stromelysin-3 and insulin-like growth factor II in tumors of ectodermal, mesodermal, and endodermal origin: indicator of a fetal cell phenotype. J. Clin. Endocrinol. Metab., 82: 1917-1922, 1997.[Abstract/Free Full Text]
  22. Orimo A., Inoue S., Minowa O., Tominaga N., Tomioka Y., Sato M., Kuno K., Hiroi H., Shimizu Y., Suzuki M., Noda T., Muramatsu M. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen responsive finger protein (efp) gene, which is a direct target of estrogen receptor {alpha} (ER {alpha}). Proc. Natl. Acad. Sci. USA, 96: 12027-12032, 1999.[Abstract/Free Full Text]
  23. Inoue S., Orimo A., Hosoi T., Kondo S., Toyoshima H., Kondo T., Ikegami A., Ouchi Y., Orimo H., Muramatsu M. Genomic binding-site cloning reveals a novel estrogen responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. USA, 90: 11117-11121, 1993.[Abstract/Free Full Text]
  24. Kraus W. L., Katzenellenbogen B. S. Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology, 132: 2371-2379, 1993.[Abstract/Free Full Text]
  25. Tlsty T. D., Hein P. W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev., 11: 54-59, 2001.[CrossRef][Medline]
  26. Kurman R. J., Norris H. J. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer (Phila.)., 49: 2547-2559, 1982.[CrossRef][Medline]
  27. Sappino A. P., Skalli O., Jackson B., Schurch W., Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer, 41: 707-712, 1988.[Medline]
  28. Chiquet-Ehrismann R., Kalla P., Pearson C. A. Participation of tenascin and transforming growth factor-ß in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res., 49: 4322-4325, 1989.[Abstract/Free Full Text]
  29. Serini G., Bochaton-Piallat M. L., Ropraz P., Geinoz A., Borsi L., Zardi L., Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-ß1. J. Cell Biol., 142: 873-881, 1998.[Abstract/Free Full Text]
  30. Poulsom R., Pignatelli M., Stetler-Stevenson W. G., Liotta L. A., Wright P. A., Jeffery R. E., Longcroft J. M., Rogers L., Stamp G. W. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol., 141: 389-396, 1992.[Abstract]
  31. Frazier K. S., Grotendorst G. R. Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int. J. Biochem. Cell Biol., 29: 153-161, 1997.[CrossRef][Medline]
  32. Ponten F., Ren Z., Nister M., Westermark B., Ponten J. Epithelial-stromal interactions in basal cell cancer: the PDGF system. J. Investig. Dermatol., 102: 304-309, 1994.[CrossRef][Medline]
  33. Berndt A., Kosmehl H., Mandel U., Gabler U., Luo X., Celeda D., Zardi L., Katenkamp D. TGF ß and bFGF synthesis and localization in Dupuytren’s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J., 27: 1014-1020, 1995.[Medline]
  34. Herbst A. L., Anderson S., Hubby M. M., Haenszel W. M., Kaufman R. H., Noller K. L. Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: a case-control study. Am. J. Obstet. Gynecol., 154: 814-822, 1986.[Medline]
  35. Weiderpass E., Baron J. A., Adami H. O., Magnusson C., Lindgren A., Bergstrom R., Correia N., Persson I. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet, 353: 1824-1828, 1999.[CrossRef][Medline]
  36. Seemayer T. A., Lagace R., Schurch W., Tremblay G. Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am. J. Surg. Pathol., 3: 525-533, 1979.[Medline]
  37. Nicosia R. F., Tuszynski G. P. Matrix-bound thrombospondin promotes angiogenesis in vitro. J. Cell Biol., 124: 183-193, 1994.[Abstract/Free Full Text]
  38. Jiang B. H., Agani F., Passaniti A., Semenza G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase1: involvement of HIF-1 in tumor progression. Cancer Res., 57: 5328-5335, 1997.[Abstract/Free Full Text]
  39. Maxwell P. H., Dachs G. U., Gleadle J. M., Nicholls L. G., Harris A. L., Stratford I. J., Hankinson O., Pugh C. W., Ratcliffe P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA, 94: 8104-8109, 1997.[Abstract/Free Full Text]
  40. Liu Y., Cox S. R., Morita T., Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ. Res., 77: 638-643, 1995.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Zhang, L. Fu, J. Fu, L. Hu, H. Yang, T.-H. Rong, Y. Li, H. Liu, S.-B. Fu, Y.-X. Zeng, et al.
Fibroblast Growth Factor Receptor 2-Positive Fibroblasts Provide a Suitable Microenvironment for Tumor Development and Progression in Esophageal Carcinoma
Clin. Cancer Res., June 15, 2009; 15(12): 4017 - 4027.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. Mishra, P. J. Mishra, R. Humeniuk, D. J. Medina, G. Alexe, J. P. Mesirov, S. Ganesan, J. W. Glod, and D. Banerjee
Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells
Cancer Res., June 1, 2008; 68(11): 4331 - 4339.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Granot, Y. Addadi, V. Kalchenko, A. Harmelin, L. A. Kunz-Schughart, and M. Neeman
In vivo Imaging of the Systemic Recruitment of Fibroblasts to the Angiogenic Rim of Ovarian Carcinoma Tumors
Cancer Res., October 1, 2007; 67(19): 9180 - 9189.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tsujino, I. Seshimo, H. Yamamoto, C. Y. Ngan, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, and M. Monden
Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2082 - 2090.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. G. Bagley, W. Weber, C. Rouleau, and B. A. Teicher
Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy
Cancer Res., November 1, 2005; 65(21): 9741 - 9750.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Miyazawa, A. Mitoro, S. Kawashiri, K. K. Chada, and K. Imai
Expression of Mesenchyme-Specific Gene HMGA2 in Squamous Cell Carcinomas of the Oral Cavity
Cancer Res., March 15, 2004; 64(6): 2024 - 2029.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orimo, A.
Right arrow Articles by Muramatsu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orimo, A.
Right arrow Articles by Muramatsu, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online